Stockscreener 앱 받기
24.37
0.16%
0.04
시간 외 거래:
24.37
전일 마감가:
$24.33
열려 있는:
$24.37
하루 거래량:
1.34M
Relative Volume:
0.52
시가총액:
$3.08B
수익:
$715.22M
순이익/손실:
$-250.10M
주가수익비율:
-12.00
EPS:
-2.03
순현금흐름:
$-205.58M
1주 성능:
+6.19%
1개월 성능:
+36.22%
6개월 성능:
-17.08%
1년 성능:
-35.29%
1일 변동 폭
$23.88
$24.63
1주일 범위
$22.89
$24.64
52주 변동 폭
$16.10
$41.94
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
APLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
24.37 | 3.00B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
11 Best Short-Term Stocks to Invest in - Insider Monkey
Apellis wins FDA label expansion for Empaveli in rare kidney disorders - MSN
Fierce Biotech Layoff Tracker 2025: Tune, Bicycle let go of 25% of staff - Fierce Biotech
Apellis Pharmaceuticals' Empaveli Faces Market Challenges and Physician Preferences - AInvest
Hold Rating for Apellis Pharmaceuticals’ Empaveli Amid Market Challenges and Physician Preferences - TipRanks
Apellis Pharmaceuticals (APLS) Sees Target Price Raised by Citig - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2025 Earnings Call Transcript - Insider Monkey
Apellis Pharmaceuticals’ Earnings Call: A Balanced Outlook - TipRanks
Published on: 2025-08-04 22:37:11 - beatles.ru
Why Apellis Pharmaceuticals Shares Are Gaining Attention - TipRanks
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN
Apellis Pharmaceuticals Inc. Stock Analysis and ForecastInvest smarter with actionable stock recommendations - Jammu Links News
Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug - MSN
Apellis’ EMPAVELI Approved by FDA for Rare Kidney Diseases - MSN
When is Apellis Pharmaceuticals Inc. stock expected to show significant growthBuild a portfolio with strong long-term growth - Jammu Links News
How many analysts rate Apellis Pharmaceuticals Inc. as a “Buy”Exceptional profit potential - Jammu Links News
What makes Apellis Pharmaceuticals Inc. stock price move sharplyDiscover undervalued stocks ready to soar - Jammu Links News
Is Apellis Pharmaceuticals Inc. a growth stock or a value stockFree Stock Movement Tracking - Jammu Links News
How strong is Apellis Pharmaceuticals Inc. company’s balance sheetBuild wealth steadily with proven investment techniques - Jammu Links News
How volatile is Apellis Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough growth with proven strategies - Jammu Links News
What analysts say about Apellis Pharmaceuticals Inc. stockConsistent triple-digit returns - Jammu Links News
What catalysts could drive Apellis Pharmaceuticals Inc. stock higher in 2025High-octane investment gains - Jammu Links News
What drives Apellis Pharmaceuticals Inc. stock priceCapitalize on market trends before they peak - Jammu Links News
What institutional investors are buying Apellis Pharmaceuticals Inc. stockFree Stock Movement Tracking - Jammu Links News
Why is Apellis Pharmaceuticals Inc. stock attracting strong analyst attentionUnlock exclusive stock market forecasts - Jammu Links News
How does Apellis Pharmaceuticals Inc. generate profit in a changing economyUnlock powerful portfolio optimization tools - Jammu Links News
What are Apellis Pharmaceuticals Inc. company’s key revenue driversBuild a portfolio that stands the test of time - Jammu Links News
Apellis Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Apellis Pharmaceuticals: Navigating Q2 Earnings and Building a Complement-Driven Ophthalmology Powerhouse - AInvest
What are the latest earnings results for Apellis Pharmaceuticals Inc.Free Stock Target Finder For Fast Growth - jammulinksnews.com
Apellis Pharmaceuticals (APLS) Stock Forecast and Price Target 2025 - MarketBeat
Apellis Pharmaceuticals: The Picture Becomes Clearer (NASDAQ:APLS) - Seeking Alpha
Apellis Pharmaceuticals Surges 17.6% on Higher Price Target from Scotiabank - AInvest
Apellis (APLS) Price Target Raised as Market Stabilizes - GuruFocus
RBC Capital Raises Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News - GuruFocus
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $19 to $57 - 富途牛牛
Raymond James Adjusts Price Target for Apellis (APLS) After Q2 E - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Surges 25% Yet Its Low P/S Is No Reason For Excitement - 富途牛牛
APLS: Cantor Fitzgerald Raises Price Target for Apellis Pharmace - GuruFocus
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say - MSN
Analyst Raymond James Lowers Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News - GuruFocus
Apellis: Raymond James Maintains Outperform, PT Down to $50 - AInvest
Apellis (APLS) Price Target Raised by Citi Following Strong Q2 R - GuruFocus
Cautious Outlook on Apellis Pharmaceuticals: Hold Rating Amidst Modest Syfovre Growth and Empaveli Expansion - TipRanks
Apellis Pharmaceuticals Reports Q2 Revenue Below Expectations, Celebrates FDA Approval of EMPAVELI - AInvest
Apellis Pharmaceuticals Inc (APLS) Q2 2025 Earnings Call Highlig - GuruFocus
Apellis Pharmaceuticals Reports Q2 2025 Earnings - TipRanks
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus
Apellis Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):